BioFire - Model RP2.1 - COVID-19 and Respiratory Pathogen Detection System
From Panels
SARS-CoV-2 is a top concern for patients and clinicians, but several respiratory pathogens can cause nearly indistinguishable symptoms. The FDA De Novo authorized BioFire RP2.1 Panel is a frontline test to help clinicians quickly diagnose respiratory infections, including COVID-19, influenza, RSV, and many others.
Details:
The BioFire RP2.1 Panel uses a syndromic approach to accurately detect and identify the pathogens most commonly associated with respiratory infections. Fast and comprehensive, the BioFire RP2.1 Panel offers a run time of about 45 minutes, enabling high efficiency and throughput on the BioFire® FilmArray® 2.0 and the BioFire® FilmArray® Torch Systems. Rapid respiratory PCR test results may enable better-informed diagnosis and treatment of patients. Quick turnaround on a broad menu of pathogens may also help clinicians make vital decisions regarding admission, isolation, cohorting, and additional diagnostic testing.
Products Details
Detection of respiratory pathogens just got faster and more comprehensive! The latest and greatest in respiratory solutions from BioFire includes:
- The addition of Bordetella parapertussis pathogen target
- An unprecedented run time of about 45 minutes
- Optimized assays to improve overall sensitivity
The BioFire RP2 is available on the BioFire® FilmArray® 2.0 and the BioFire® FilmArray® Torch Systems.
BioFire’s original Respiratory Panel delivers results on 17 viral and 3 bacterial targets in about one hour. The BioFire RP is available on all existing instruments, including the BioFire®FilmArray® 1.5, BioFire 2.0, and the high throughput BioFire Torch.
RESPIRATORY PANEL MENU
Overall 97.1% Sensitivity and 99.3% Specificity 6
Sample Type: Nasopharyngeal swab in transport media
VIRUSES:
- Adenovirus
- Coronavirus HKU1
- Coronavirus NL63
- Coronavirus 229E
- Coronavirus OC43
- Human Metapneumovirus
- Human Rhinovirus/Enterovirus
- Influenza A
- Influenza A/H1
- Influenza A/H3
- Influenza A/H1-2009
- Influenza B
- Parainfluenza Virus 1
- Parainfluenza Virus 2
- Parainfluenza Virus 3
- Parainfluenza Virus 4
- Respiratory Syncytial Virus
BACTERIA:
- Bordetella parapertussis*
- Bordetella pertussis
- Chlamydia pneumoniae
- Mycoplasma pneumoniae
BioFire RP results have been shown to significantly reduce ICU days5 and duration of antibiotic use4. Optimize patient management with clinically actionable results.
The BioFire RP has been shown to reduce overall healthcare costs. Significant savings were demonstrated in an adult ICU population in both patients that tested positive for a respiratory pathogen as well as those that tested negative.5
Customer reviews
No reviews were found for BioFire - Model RP2.1 - COVID-19 and Respiratory Pathogen Detection System. Be the first to review!